Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-05-31
2011-05-31
Bunner, Bridget E (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S351000, C530S387300, C435S069100, C930S143000, C514S012200, C514S903000
Reexamination Certificate
active
07951371
ABSTRACT:
This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β. receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4758549 (1988-07-01), Mitsuhashi et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4822605 (1989-04-01), Powell
patent: 4849509 (1989-07-01), Thurin et al.
patent: 4959457 (1990-09-01), Bringman
patent: 5082783 (1992-01-01), Ernst et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5795964 (1998-08-01), Browning et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 7060667 (2006-06-01), Browning et al.
patent: 7255854 (2007-08-01), Browning et al.
patent: 7309492 (2007-12-01), Browning et al.
patent: 7427403 (2008-09-01), Browning et al.
patent: 7452530 (2008-11-01), Browning et al.
patent: 7459537 (2008-12-01), Browning et al.
patent: 2002/0001585 (2002-01-01), Browning et al.
patent: 2002/0039580 (2002-04-01), Browning et al.
patent: 2002/0197254 (2002-12-01), Browning et al.
patent: 2004/0058394 (2004-03-01), Garber et al.
patent: 2004/0198635 (2004-10-01), Browning et al.
patent: 2005/0037003 (2005-02-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 2006/0104971 (2006-05-01), Garber et al.
patent: 2006/0134102 (2006-06-01), LePage et al.
patent: 2006/0222644 (2006-10-01), Garber et al.
patent: 2006/0280722 (2006-12-01), Browning et al.
patent: 2007/0116668 (2007-05-01), Browning et al.
patent: 2007/0154476 (2007-07-01), Browning et al.
patent: 2008/0219967 (2008-09-01), Browning et al.
patent: 3218121 (1983-11-01), None
patent: 0058481 (1982-08-01), None
patent: 0367575 (1990-05-01), None
patent: 0509553 (1992-10-01), None
patent: 0873998 (1998-10-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/01121 (1996-01-01), None
patent: WO-96/22788 (1996-08-01), None
patent: WO-96/23071 (1996-08-01), None
patent: WO-97/03678 (1997-02-01), None
patent: WO-97/03687 (1997-02-01), None
patent: WO-97/04658 (1997-02-01), None
patent: WO-98/17313 (1998-04-01), None
patent: WO-98/18928 (1998-05-01), None
patent: WO-2007/146414 (2007-12-01), None
Abe, Yasuhito et al., “Expression of Membraine-associated Lymphotoxin/Tumor Necrosis Factor-β on Human Lymphokine-activated Killer Cells,”Jpn. J. Cancer Res., vol. 82:23-26 (1991).
Abe, Yasuhito et al., “Studies of Membrane-Associated and Soluble (Secreted) Lymphotoxin in Human Lymphokine-Activated T-Killer Cells in Vitro,”Lymphokine and Cytokine Research, vol. 11(2):115-121 (1992).
Acharya, S.K. et al., “A preliminary open trial on interferon stimulator (SNMC) derived fromGlycyrrhiza glabrain the treatment of subacute hepatic failure,”Indian J. Med. Res. [B], vol. 98:69-74 (1993).
Aebersold, Ruedi H. et al., “Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose,”Proc. Natl. Acad. Sci. USA, vol. 84:6970-6974 (1987).
Aggarwal, Bharat B. et al., “Human Lymphotoxin,”The Journal of Biological Chemistry, vol. 259(1):686-691 (1984).
Aggarwal, Bharat B. et al., “Primary Structure of Human Lymphotoxin Derived from 1788 Lymphoblastoid Cell Line,”The Journal of Biological Chemistry, vol. 260(4):2334-2344 (1985).
Akashi, Makoto et al., “Lymphotoxin: Stimulation and Regulation of Colony-Stimulating Factors in Fibroblasts,”Blood, vol. 74(7):2383-2390 (1989).
Alderson, Mark R. et al., “Regulation of apoptosis and T cell activation by Fas-specific mAb,”International Immunology, vol. 6(11):1799-1806 (1994).
Alexopoulou, Lena et al., “Immunoregulatory Activities of Transmembrane TNF Revealed in Transgenic and Mutant Mice,”6th International TNF Congress, p. 228, No. 110 (1996).
Alimzhanov, Marat B. et al., “Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice,”Proc. Natl. Acad. Sci. USA, vol. 94:9302-9307 (1997).
Amiri, Payman et al., “Tumour necrosis factor α restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice,”Nature, vol. 356:604-607 (1992).
Anderson, W. French, “Human gene therapy,”Nature, vol. 392:25-30 (1998).
Andersson, Ulf et al., “Characterization of individual tumor necrosis factor α- and β-producing cells after polyclonal T cell activation,”Journal of Immunological Methods, vol. 123:233-240 (1989).
Andrews, Janet S. et al., “Characterization of the Receptor for Tumor Necrosis Factor (TNF) and Lymphotoxin (LT) on Human T Lymphocytes, TNF and LT Differ in Their Receptor Binding Properties and the Induction of MHC Class I Proteins on a Human CD4+ T Cell Hybridoma,”The Journal of Immunology, vol. 144(7):2582-2591 (1990).
Androlewicz, Matthew J. et al., “Lymphotoxin Is Expressed as a Hetermeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma,”The Journal of Biological Chemistry, vol. 267(4):2542-2547 (1992).
Armitage, Richard J. et al., “Molecular and biological characterization of a murine ligand for CD40,”Nature, vol. 357:80-82 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. Exp. Med., vol. 177:1439-1450 (1993).
Badenhoop, K. et al., “TNF-α gene polymorphisms in Type 1 (insulin-dependent) diabetes mellitus,”Diabetologia, vol. 32:445-448 (1989).
Baens, Mathijs et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid,”Genomics, vol. 16:214-218 (1993).
Banks, Theresa A. et al., “Lymphotoxin-α-Deficient Mice,”The Journal of Immunology, vol. 155:1685-1693 (1995).
Barnetson, “Hypersensitivity—Type IV,” Mosby-Year Book Europe Ltd., Chpt. 22, pp. 22.1-22.12 (1993).
Bernstein, David I. et al., “Effects of therapy with an immunomodulator (imiquimod, R-837) alone with the acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development,”Antiviral Research, vol. 20:45-55 (1993).
Bethell, Delia B. et al., “Pathophysiologic and Prognostic Role of Cytokines in Dengue Hemorrhagic Fever,”JID, vol. 177:778-782 (1998).
Beutler, B. et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, vol. 229:869-871 (1985).
Beutler, Bruce et al., “The History, Properties, and Biological Effects of Cachectin,”Biochemistry, vol. 27(20):7575-7582 (1988).
Bowie, James U. et
Benjamin Christopher D.
Browning Jeffrey L.
Hochman Paula S.
Biogen Idec MA Inc.
Bunner Bridget E
Howard Zachary C
Nelson Mullins Riley & Scarborough LLP
Williams Megan E.
LandOfFree
Soluble lymphotoxin-β receptor fusion protein and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble lymphotoxin-β receptor fusion protein and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble lymphotoxin-β receptor fusion protein and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691662